The name is the button.

An agent writes the code now, and a human thumb hovers over Accept all a hundred times a day. The honest question of this decade is what, exactly, you just accepted. So I read the diff.

Eight years as a backend engineer in Stockholm, back in Tokyo since 2023, and I still ship something small most nights, usually badly. My one rule: the only real review of a model is the thing you built with it. That is why there is no leaderboard on this site.

Around a hundred and forty sources come through — the labs' own posts, the papers, the tools, the runtimes and languages nobody is watching yet, the chip under the demo, and the newsletters people actually forward. What is moving gets counted so the week reads at a glance, and every few days I explain one mechanism in plain words.

A story here is a headline, a short excerpt, one image and the link to whoever wrote it. We never reproduce the post; the images belong to their authors. A post written in Japanese appears in Japanese, exactly as it was published, and the link goes to the original.

— Yuki Halvorsen, Tokyo

← Accept All Archive

Bloomberg TechnologyValley

Citrini Bets on Life Sciences Stocks After Claude AI Drug Study

10.20

Life sciences companies stand to gain from a surge in artificial intelligence fueled drug discovery, says Citrini Research after testing Anthropic PBC’s Claude Science.

Models & releases

Read at Bloomberg Technology ↗

One letter a week, starting soon.

Latest

Citrini Bets on Life Sciences Stocks After Claude AI Drug Study

Related

ValleyEka is worth $1.45B thanks to a physical AI model that has experts raving TechCrunch AI

SiliconOblivion gamer uses Claude AI to boost average FPS gains up to 48%, stutters slashed by 90% Tom's Hardware

US bans Deepseek technology across federal civilian agencies The Decoder

Toolsb11755 llama.cpp releases

LabsIntroducing Gemini for government services Google Cloud AI

Toolsb11753 llama.cpp releases